v3.26.1
Condensed Consolidated Statements of Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Condensed Consolidated Statements of Loss    
Product revenue, net $ 238 $ 0
License and other revenue 0 0
Total revenues 238  
Operating Expenses    
Cost of product sales 14 0
Research and development, net of tax credits 3,251 4,978
General and administrative 4,824 5,167
Commercial 15,812 10,378
Total operating expenses 23,901 20,523
Loss from operations (23,663) (20,523)
Interest income 1,732 697
Interest expense (4,135) (935)
Net loss and comprehensive loss $ (26,066) $ (20,761)
Weighted average number of shares and pre-funded warrants outstanding, basic (in shares) 130,286,033 66,285,406
Weighted average number of shares and pre-funded warrants outstanding, diluted (in shares) 130,286,033 66,285,406
Net loss per share, basic (in dollars per share) $ (0.2) $ (0.31)
Net loss per share, diluted (in dollars per share) $ (0.2) $ (0.31)